Latest News…

Dr Jim Millen joins Oval Board

Oval Medical Technologies is pleased to announce the appointment of Dr Jim Millen to the Oval board. Jim is a physician with over 15 years’ experience in life science companies including Allergan and GSK. He has a track record of leading substantial commercial deals in pharma and biotech and brings this strength to the board […]

Continue Reading

Oval Medical represented at Conferences and Events

Oval Medical’s partner Solize Corporation will exhibit and present at the InnoPack 2015 conference in Tokyo (April 22-24th) in conjunction with the CPhI event held at TokyoBigSight. Representatives from Oval and Solize will be present to demonstrate the Oval autoinjectors and collaboration opportunities. Oval Medical has been attending and exhibiting at a number of conferences […]

Continue Reading

Completion of Innovate UK Smart Award

April 2015 Oval Medical completes Innovate UK (formerly The Technology Strategy Board) Smart Award Grant for development of manufacturing equipment for their novel container closure system. Oval Medical has developed bespoke sealing equipment for the drug container in collaboration with 3P Limited; this is a key manufacturing step for its leading edge auto injector. Commenting […]

Continue Reading

Rights Issue

March 2015 Oval Medical recently completed a £1.5m rights issue for the development of the manufacturing process for its novel autoinjector. The autoinjector facilitates the delivery of the new generation of biologics by eliminating issues including glass breakage, drug contamination and variable injection times. This equipment will form part of the manufacturing process for clinical […]

Continue Reading

New Board Member

January 2015 Oval is pleased to announce that Desmond Astley-Cooper of Turquoise Associates International joined the board in December 2014 as the representative of the Low Carbon Investment Fund (LCIF)

Continue Reading

Oval Medical awarded Innovate UK Proof of Market funding award

November 2014 Oval Medical received £25,000 to contribute to market research for its new, innovative epinephrine autoinjector for the treatment of anaphylactic shock. The incidence of allergies that can cause this serious and potentially fatal reaction is growing worldwide. Oval’s epinephrine autoinjector incorporates the same design philosophy as the first device being used for sumatriptan. […]

Continue Reading

Oval and SOLIZE enter into collaboration on injection device development

Press Release For Immediate Release Cambridge, UK. Monday, 28 April 2014 – Oval Medical Technologies Limited (“Oval”) Oval and SOLIZE enter into collaboration on injection device development. Working together to accelerate product development in the growing auto-injector market. Oval Medical Technologies Ltd (Cambridge, UK) and SOLIZE Corporation (Tokyo, Japan) have agreed to collaborate together in […]

Continue Reading

Technology Strategy Board – Smart Funding Award

Press Release For Immediate Release Oval Medical awarded Technology Strategy Board Smart funding award Cambridge, UK. 14 April 2014 – Oval Medical Technologies Limited (“Oval”) announced today they have received a Smart funding award from the UK’s innovation agency, the Technology Strategy Board, of £228,256 for a project that will progress the development of the […]

Continue Reading

Oval Medical announces new Chairman of the Board

Oval Medical Technologies Limited (“Oval”), a leading auto-injector company, has named Dr. Paul Harper as Chairman of the Board. He will be succeeding Peter Keen after his three-year tenure.  Peter has now taken the position of Chief Executive at investment fund Cambridge Innovation Capital. Dr Harper took up the role at Oval in January 2014, […]

Continue Reading